Objectives: The present study explored the possible protective effect of IgY on PA lung infection in vivo. Methods: In vivo model of acute lung infection: Balb/c mice were anaesthetized with isoflurane and PAO1 vaccine strain ± specific (S-IgY) or control (C-IgY) was inoculated intranasally. Mice were sacrificed after 2, 6 and 24h and lungs removed aseptically, weighted and suspended in PBS. A blinded observer engaged a clinical scoring system (0−5) of the mice. Lungs were homogenized, serially diluted and cultured on Conradi-Drigalski medium for estimation of bacterial load. Results: Relative lung weight: Lung weights in the S-IgY treated group were significantly reduced 24h post-infection compared to PBS controls (p < 0.03). No significant difference between C-IgY and PBS groups were observed. Clinical symptom score: The clinical score was significantly lower in the S-IgY group compared to controls after 6h (C-IgY: p < 0.05, PBS: p < 0.05). After 24h the clinical score in the S-IgY was reduced additionally compared to controls (PBS: p < 0.002, C-IgY: p < 0.04). No significant difference between C-IgY and PBS groups were observed. Quantitative bacteriology: The bacterial load of S-IgY treated mice was significantly reduced 2h post-infection compared to PBS group (p < 0.02) and C-IgY (p < 0.03) and further reduced 6h post-infection compared to both control groups (PBS: p < 0.0001, C-IgY: p < 0.03). After 24h the lung bacteriology in S-IgY treated mice was reduced by 2 logs compared to PBS (p < 0.0001) and C-IgY (p < 0.0002) groups.
Results: During the observation period 2 (1.3%) patients became chronically infected. Patients never infected or free from Pa were respectively 48 (31.4%) and 60 (39.2%) of the total. In both groups antibody titre was under the cut-off level (1.50±1.90 EU). In the group of 43 (28.1%) patients, intermittently infected by Pa, the titer of anti-Pa antibodies was significantly higher in subjects presenting a concomitant bacterial isolation than those who did not showed Pa isolation (3.03 EU ± SD 3.20, 1.72 EU ± SD 1.7, respectively) (P < 0.05).
Conclusion:
The evaluation of specific anti-Pa antibodies may be a useful way to monitor early Pa infection in patients with intermittent infection. Objectives: Children with cystic fibrosis are, unfortunately, candidates at multiple antibiotic courses, having a potential increase risk for pseudomembranous colitis with Clostridium difficile. The aim of the paper was to evaluate the frequency of C. difficile infection among children with cystic fibrosis (CF). Methods: Retrospective analysis over a ten years period was done, using the information from our CF center's database. In all the patients, only presentation with diarrhea occurred during antibiotherapy were taken into consideration. Diagnosis test for C. difficile infection was performed by enzyme immunoassay for detection of toxins A and B.
Results: Over a ten years period, 308 patients with cystic fibrosis were admitted in our clinic; only five of them (1.62%) were diagnosed with C. difficile infection. Patients were diagnosed in the last 4 years, by the detection e of toxin A or toxin A and B (in 2 patients) in the presence of diarrhea; they had a favorable outcome, with a good response to treatment (metronidazole in 3 cases, metronidazole and vancomycin in 2 cases). All patients had chronic Pseudomonas aeruginosa infection and received more than fourteen days of antibiotics.
Clostridium difficile infection should be consider for evaluation in cystic fibrosis patients with diarrhea who receive antibiotics. Special attention is necessary when antibiotherapy is given for a long time, as commonly reccomended in cystic fibrosis patients.
